• Jose Manuel Pereira, Jose Artur Paiva, and Jordi Rello.
• Emergency and Intensive Care Department, Centro Hospitalar S. João EPE, Faculdade de Medicina da Universidade do Porto, Porto, Portugal. jmcrpereira@yahoo.com
• Semin Respir Crit Care Med. 2012 Jun 1;33(3):272-83.

AbstractDespite all advances in its management, community-acquired pneumonia (CAP) is still an important cause of morbidity and mortality requiring a great consumption of health, social, and economic resources. An early and adequate severity assessment is of paramount importance to provide optimized care to these patients. In the last 2 decades, this issue has been the subject of extensive research. Based on 30 day mortality, several prediction rules have been proposed to aid clinicians in deciding on the appropriate site of care. In spite of being well validated, their sensitivity and specificity vary, which limits their widespread use. The utility of biomarkers to overcome this problem has been investigated. At this moment, their full clinical value remains undetermined, and no single biomarker is consistently ideal for assessing CAP severity. Biomarkers should be seen as a complement rather than superseding clinical judgment or validated clinical scores. The search for a gold standard is not over, and new tools, like bacterial DNA load, are in the pipeline. Until then, CAP severity assessment should be based in three key points: a pneumonia-specific score, biomarkers, and clinical judgment.Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

13 keywords...

hide…